newsfilter
← Latest News
GlobeNewswire·

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal